INTRODUCTION
The proteasome is a critical component of the ubiquitin-proteasome system, which is responsible for the regulation and degradation of the majority of intracellular proteins, including those involved in growth control, cell-cycle regulation and apoptosis (1, 2) . Inhibition of the proteasome leads to stabilization and accumulation of these proteasome substrates, resulting in concomitant activation of pro-and anti-proliferative signals, disruption of cell-cycle regulation and, ultimately, activation of apoptotic pathways and cell death (3, 4) . As MLN9708 (Millennium Pharmaceuticals, Inc.) is an investigational small-molecule proteasome inhibitor currently being developed for a broad range of human malignancies (8, 9) . MLN9708 is a citrate ester that immediately hydrolyzes to its biologically active form MLN2238 upon exposure to aqueous solutions or plasma in preclinical studies ( Figure 1 ). Like bortezomib, MLN2238 is an N-capped dipeptidyl leucine boronic acid that selectively, reversibly and potently inhibits the β5 site of the 20S proteasome. However, MLN2238 has a significantly shorter proteasome dissociation half-life that we believe influences its biodistribution (9) . We believe while a slowly reversible inhibitor such as bortezomib maintains a long duration of proteasome inhibition in red blood cells (RBC) and is slow to equilibrate and redistribute to tumor tissues, a more rapidly reversible inhibitor such as MLN2238 can dissociate faster from RBC proteasomes and can more readily enter tumor tissues. Consistent with this hypothesis, we have demonstrated that compared to bortezomib, MLN2238 has a greater tumor-to-blood ratio of proteasome inhibition that ultimately translated into improved tumor pharmacodynamic (PD) response and antitumor activity in several tumor xenograft models (9) . For decades, tumor xenograft models, which involve the subcutaneous inoculation of human tumor cell lines or tumor tissue fragments into immunocompromised mouse hosts, have been the mainstay of in vivo models for drug discovery in oncology. The robustness of these models allows for the rapid evaluation and prioritization of potential drug candidates into clinical trials. While virtually all new cancer therapies developed in the modern era have gone through this paradigm, these tumor xenograft models do not fully depict the biology and heterogeneity of their human disease counterpart (10) (11) (12) (13) (14) . In contrast, the de novo diseases found in most genetically engineered mouse (GEM) models of cancer often faithfully mimic the stepwise pathological progression of human cancers: from the premalignant neoplastic stage that carries the initiating tumorigenic genetic mutations within their native tumor microenvironment, to the fully transformed cancer stage that resembles the genetic heterogeneity of their human counterparts (15, 16) . However, accurate depiction of the human disease often comes with significant logistical tradeoffs, necessitating prohibitively large study cohorts for establishing statistical significance (13) . In addition, disease progression and tumor onset are often slow and lengthy in these GEM models (months to years), further impeding their broader use in most fast-paced drug discovery settings.
Here, we sought to take advantage of both the robustness of the tumor xenograft models and the fidelity of the GEM models. We focused on evaluating and directly comparing the in vivo activity of MLN2238 and bortezomib in a variety of mouse models of hematological malignancies, including both tumor xenograft models derived from a human lymphoma cell line and primary human lymphoma tissue, to GEM models of plasma cell malignancies (PCM). The robustness of the tumor xenograft models allowed us to rapidly assess and relate the tumor PD profile of these molecules to their antitumor activities, while the fidelity of GEM models allowed us to preclinically assess their effects on tumor burden, osteolytic bone disease and terminal outcome analogous to the human disease. We believe this comprehensive approach will lead to a more thorough 
MATERIALS AND METHODS

Animal care
Strain CB17-severe combined immunodeficient (SCID) and non-obese diabetic (NOD)-SCID mice were obtained from Charles River Laboratories (Wilmington, MA 
Compounds
For in vivo studies, bortezomib (dissolved in 0.9% saline) and MLN2238 (dissolved in 5%
hydroxypropyl-beta-cyclodextrin [HPβCD] ) were dosed at their maximum tolerated dose (MTD) for the specified mouse strain and model, unless otherwise specified.
Tumor xenograft models of activated B-cell diffuse large B-cell lymphoma
For the OCI-Ly10 model, freshly dissociated OCI-Ly10 diffuse large B-cell lymphoma cells of the inoculated subcutaneously into the right flank of CB17-SCID mice as previously described (18) . For the PHTX22L model, lymphoma tissue surgically isolated from a 71-year-old male with ABC-DLBCL was maintained via serial passage of the tumor fragment (~20 mg) between the right dorsal flanks of NOD-SCID mice as previously described (18) . For PD studies, subcutaneous tumors (~600 mm 3 in size) were harvested, processed and analyzed for specific inhibition of β5 activity of the 20S proteasome as previously described (9) .
Efficacy studies were performed as previously described (9) .
Splenomegaly and mouse immunoglobulin levels
Spleens harvested from iMyc Cα /Bcl-X L mice reaching humane end points were weighed as a measurement for splenomegaly. Terminal blood samples were collected by cardiac puncture, and mouse immunoglobulin and cytokine levels were determined by Searchlight ® Protein Array Analysis (Aushon Biosystems, Woburn, MA).
Cell culture and cell viability assay
Parental DP54 cells were stably transfected with pDEST12.2-mIgK-Luc, which constitutively expresses the firefly luciferase gene (Luc) under the control of a mouse immunoglobulin kappa light-chain promoter/enhancer similar to that previously described (19) . Transfection was performed using Nucleofector ® Kit V (Lonza, Köln, Germany; VCA1003). One clone was selected by limited dilution in the presence of 0.8 mg/mL G418 and was designated DP54-Luc. DP54-Luc cells were maintained in RPMI-1640 media supplemented with 25 mM HEPES, 15% FBS, 1 mM sodium pyruvate, 2 mM L-glutamine, 50 μM β-mercaptoethanol, 0.5 ng/mL interleukin-6, 0.8 mg/mL G418 and 50 units/mL each of penicillin and streptomycin at 37°C with 5% CO 2 . ATPLite TM in vitro cell viability studies were performed according to the manufacturer's instructions (Perkin-Elmer Life Sciences, Waltham, MA) as previously described (20) .
Disseminated mouse model and IVIS ® bioluminescence Imaging
Research. Tumor burden was monitored by IVIS ® bioluminescence imaging (BLI) as previously described (9) .
Osteolytic bone disease and computed tomography imaging
Ex vivo computed tomography (CT) was performed on formalin-fixed cadavers on an eXplore scanner (GE Healthcare, UK), two mice per session in a two-mouse gantry. Parameters for acquisition were the following: in-plane resolution 46 μm 2 , 720 views, two frames/view, angel of increment 1°, exposure time 100 ms, voltage 80 kV and current 450 μA. All renderings were analyzed using Analyze 4.0 software. For analysis of the cranium, 3D renderings of the caudal aspect were cropped to include the sagittal bones, sagittal sutures and parietal sutures, before being saved as 2D images. Cranial suture widening was measured in sagittal suture separation areas (SSSA) and calculated by displaying the area of displacement between the sutures in a singlevoxel layer, before being converted to mm 3 by multiplying the voxel dimensions. Cranial bone erosion was assessed by bone surface roughness analysis as described previously (21) .
Statistical analyses
Sample size determination and power analysis were calculated with the STT3 function from nQuery Adviser ® (Version 7, Statistical Solutions). Simulated survival data were generated from a pseudo-random number generator under piece-wise constant hazard assumption and compared with log-rank statistics. Power was defined as the percentage of simulations in which the statistic indicates a significant outcome. For efficacy studies, survival curves and median overall survivals were generated using the Kaplan-Meier method. Hazard ratios, 95% confidence intervals (CI) and p-values were calculated based on a Cox proportional-hazard model, with treatment and gender as co-variants (22) . A hazard ratio of <1 indicated an advantage of drug treatment over untreated controls. Efficacy data were analyzed using a linear mixed effect regression model as previously described (9) . Statistical significance for the differences in mouse IgG2a levels, spleen weights and SSSAs
Research.
on January among treatment groups were determined by one-way ANOVA and Dunnett's adjustment to account for multiple comparisons. A P value of <0.05 was considered significant.
RESULTS
MLN2238 demonstrates antitumor activity in OCI-Ly10 subcutaneous ABC-DLBCL xenograft model
We first evaluated and compared the in vivo activity of MLN2238 and bortezomib in the OCI-Ly10 Figure 2B , ii).
MLN2238 demonstrates antitumor activity in PHTX22L primary human ABC-DLBCL xenograft model
We then evaluated and compared the in vivo activity of MLN2238 and bortezomib in the PHTX22L Figure 2D , i). Importantly, MLN2238 also showed strong antitumor activity in the PHTX22L model even when dosed at sub-MTD levels of 5, 7, and 11 mg/kg on various dosing schedules (T/C ranges from 0.04 to 0.16, P < 0.001 for all; Figure 2D , ii). (17, 24) .
MLN2238 demonstrates antitumor activity in the iMyc
The short latency, full penetrance and key resemblance to the human disease provides for a great preclinical GEM model to evaluate MLN2238 and bortezomib.
Using the survival data from our earlier study (17), we simulated the hypothetical effects of different drug treatments in prolonging overall survival of iMyc Cα /Bcl-X L mice in silico. As shown in Supplementary Figure 3C ). 
Osteolytic bone disease in the iMyc
DISCUSSION
Antitumor activity of MLN2238 across multiple DLBCL subtypes
DLBCL is a non-Hodgkin lymphoma that has been classified into multiple subtypes based on distinct gene expression profiles (26) . The GCB-subtype likely originates from germinal center B-cells, whereas the more aggressive ABC-subtype likely arises from post-germinal center activated B-cells that are blocked from undergoing plasmacytic differentiation. A recent multicenter study with relapsed/refractory DLBCL patients (n = 49) suggested that bortezomib in combination with doxorubicin-based chemotherapy may preferentially improve the clinical outcome of patients with the ABC-subtype (27) . Here, we demonstrated the improved PD and antitumor activity of MLN2238 compared to bortezomib in two mouse models of ABC-DLBCL: the OCILy10 and PHTX22L models. In addition, we have recently shown that MLN2238 also has improved antitumor activity in the OCI-Ly7 model of the GCB-subtype (GCB-DLBCL) and the WSU-DLCL-2 model that was distinct from either the ABC-or GCB-subtypes (non-ABC-/non-GCB-DLBCL) (9) . Together, our results suggest that MLN2238 has the potential to show broad activity across multiple DLBCL subtypes, extending beyond those seen with bortezomib.
Manifestation of osteolytic bone disease in the cranium
Research. (17) . The unprecedentedly large number of mice we have herein generated not only afforded us the ability to confirm and validate our original findings with respect to tumor penetrance, latency, and origin of the Myc-and Bcl-X L -driven de novo malignancy, but also allowed us to validate the occurrence of osteolytic bone disease and, most importantly, discover the manifestation of cranial osteolytic lesions that were previously unnoticed. It will be of great importance for future studies to determine whether these cranial suture separations and erosions are idiosyncrasies particular to the myeloma-like bone disease in iMyc Cα /Bcl-X L mice, or pathologies common to metastatic bone diseases in other GEM models of human cancer. Nevertheless, our experience highlighted another important practical lesson for implementing GEM models: new tumor phenotypes may emerge and may even be susceptible to changes as mouse lines are crossed and backcrossed into different common non-segregating backgrounds (28) (29) (30) (31) , thus requiring in-depth validation before use in preclinical studies (13) .
Future use of the iMyc
Cα /Bcl-X L model
This is the first study to demonstrate the preclinical utility and translational relevance of the iMyc Cα /Bcl-X L GEM model of PCM. We showed that MLN2238 prolonged overall survival, reduced splenomegaly, and 
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Page 19 of 26 July 15, 2011 when fully characterized, will be used to identify the specific genetic aberrations responsible for bortezomibresistance and may provide invaluable in vitro and in vivo tools for future drug screening and pharmacogenetic investigations. In particular, the activity of MLN9708 in these different plasma cell tumor lines is currently being investigated.
MLN9708 in hematological malignancies
In summary, we have demonstrated the antitumor activity of MLN2238 in a variety of mouse models of B-cell lymphoma and PCM, including tumor xenograft models derived from both a human cell line and primary human tumor tissue, and GEM models that recapitulated key features of the human diseases. In preclinical studies, MLN9708 immediately hydrolyzes to its biologically active form MLN2238 upon exposure to aqueous solutions or plasma. Research. *Simulated scenarios in silico; † Changes in median overall survival compared to untreated controls; ‡ Number of animals required in each treatment group for specified statistical power; § Based on data from our previous study (17) . 
